Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.2%. By the end of trading, Regeneron Pharmaceuticals fell $9.69 (-4.1%) to $224.88 on average volume. Throughout the day, 1,511,101 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1,232,100 shares. The stock ranged in price between $224.43-$234.25 after having opened the day at $233.06 as compared to the previous trading day's close of $234.57. Other companies within the Drugs industry that declined today were: Senesco Technologies ( SNTI), down 77.9%, Mast Therapeutics ( MSTX), down 41.5%, Bacterin International Holdings ( BONE), down 16.7% and Anthera Pharmaceuticals ( ANTH), down 10.8%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $21.9 billion and is part of the health care sector. The company has a P/E ratio of 31.8, above the S&P 500 P/E ratio of 17.7. Shares are up 37.1% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front, Halozyme Therapeutics ( HALO), up 24.8%, Enzon Pharmaceuticals ( ENZN), up 15.6%, Ventrus Biosciences ( VTUS), up 14.8% and StemCells ( STEM), up 14.6% , were all gainers within the drugs industry with Biogen Idec ( BIIB) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)